Gilead chief medical officer Merdad Parsey stated that the promising clinical data for intravenous remdesivir in treating hospitalized patients made it "clear that efforts were needed to investigate the drug's potential in the outpatient setting."The good news for investors is that the biotech stock has other potential catalysts, notably including the anticipated U.S. and European approvals for filgotinib in treating rheumatoid arthritis.